Federated Hermes Inc. Grows Stock Position in Elanco Animal Health Incorporated $ELAN

Federated Hermes Inc. boosted its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 9.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,379,391 shares of the company’s stock after acquiring an additional 197,811 shares during the period. Federated Hermes Inc. owned 0.48% of Elanco Animal Health worth $47,921,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ELAN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Elanco Animal Health in the 1st quarter valued at $2,065,000. Goldman Sachs Group Inc. increased its holdings in Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after purchasing an additional 2,445,872 shares during the last quarter. Empowered Funds LLC raised its position in Elanco Animal Health by 35.2% in the first quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock valued at $166,000 after purchasing an additional 4,121 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Elanco Animal Health by 4.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after purchasing an additional 76,408 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its position in shares of Elanco Animal Health by 8.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 11,516 shares of the company’s stock worth $169,000 after buying an additional 944 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Monday, January 19th. UBS Group boosted their price target on shares of Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. KeyCorp reissued an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, December 10th. JPMorgan Chase & Co. upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $18.00 to $24.00 in a report on Tuesday, October 7th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Elanco Animal Health in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Elanco Animal Health currently has an average rating of “Moderate Buy” and a consensus target price of $25.11.

Insiders Place Their Bets

In other Elanco Animal Health news, insider Rajeev A. Modi purchased 4,500 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were bought at an average cost of $21.33 per share, for a total transaction of $95,985.00. Following the completion of the purchase, the insider directly owned 123,082 shares in the company, valued at approximately $2,625,339.06. This represents a 3.79% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Robert M. Vanhimbergen purchased 6,950 shares of the firm’s stock in a transaction on Thursday, December 11th. The shares were acquired at an average cost of $21.64 per share, with a total value of $150,398.00. Following the completion of the acquisition, the chief financial officer directly owned 124,233 shares in the company, valued at $2,688,402.12. The trade was a 5.93% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders bought 43,450 shares of company stock worth $937,883. 0.89% of the stock is owned by corporate insiders.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock opened at $24.22 on Friday. The business has a 50-day simple moving average of $22.99 and a 200-day simple moving average of $20.24. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $25.29. The company has a market cap of $12.03 billion, a PE ratio of 403.65, a P/E/G ratio of 3.35 and a beta of 1.87.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the previous year, the firm earned $0.13 earnings per share. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.